Inotek Pharmaceuticals is a privately held and funded biotechnology company focused on the discovery and development of innovative drugs to address serious diseases of the eye.
Inotek scientists have identified a deep pipeline of drug candidates to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for drugs to treat Glaucoma, Ocular Hypertension, Age-related Macular Degeneration and Retinal Neuropathies.
The Company’s lead program, trabodenoson (INO-8875) is a highly selective adenosine mimetic that targets the A1 sub-receptor. Trabodenoson brings a novel and elegant mechanism of action for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.
This new approach to lowering IOP augments the natural process that healthy eyes use to allow excess fluid to drain from the eye through the trabecular meshwork, and makes trabodenoson, if ultimately approved by health authorities worldwide, a valuable tool that ophthalmologist can use alone or in conjunction with any of the available medicines for glaucoma. The candidate has completed a Phase 1 and Phase2 clinical trials in patients and is currently being evaluated in a multiple-dose late Phase 2 trial.
Earum IPO Date, Price, GMP, Review & Details
In the completed clinical trials, trabodenoson was well tolerated and was shown to significantly reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Inotek, in addition to having built a first-in-class ocular drug development platform, has an experienced management team with a track record of multiple successful NDAs to advance the Company’s clinical programs towards commercialization so they can benefit patients and the physicians that help manage their ocular disease.
The Company is based in Lexington, MA